1 The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: a decision-analytic approach.

2 IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C.

3 predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis c virus genotype 1

4 portal cd4+ and cd8+ t lymphocyte correlate to intensity of interface hepatitis in chronic hepatitis c a quantificação de cd4+ e cd8+ portal em hepatite c crônica está relacionada com a intensidade da hepatite de interface

5 insulin resistance and chronic hepatitis c

6 interrelation of immunological and clinic-morphological parameters in patients with chronic hepatitis c depending on mixed cryoglobulinemia

7 liver-related morbidity and mortality in patients with chronic hepatitis c and cirrhosis with and without sustained virologic response

8 association between angiogenesis soluble factors and disease progression markers in chronic hepatitis c patients asociación entre factores angiogénicos solubles y marcadores de progresión de la enfermedad en pacientes con hepatitis crónica c

9 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

10 Current treatment of choice for chronic hepatitis C infection

11 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

12 Current treatment of choice for chronic hepatitis C infection

13 Effectiveness and Cost-Effectiveness of Triple Therapy with Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis from the Brazilian Public Health System Perspective

14 Real-world effectiveness and safety of Ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan.

15 Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography.

16 A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms

17 Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.

18 Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.

19 Surveillance and impact of occult hepatitis B virus, SEN virus, and Torque teno virus in Egyptian hemodialysis patients with chronic hepatitis C virus infection.

20 The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C.

21 Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C.

22 Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.

23 Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C.

24 Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin Regimen for Patients Infected with Chronic Hepatitis C Virus Genotype 1 in Malaysia

25 Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.

26 Chronic Hepatitis C Virus Infection in Older Adults

27 Safety and Effectiveness of a Nurse-Led Outreach Program for Assessment and Treatment of Chronic Hepatitis C in the Custodial Setting

28 Telaprevir for previously untreated chronic hepatitis C virus infection

29 Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis C

30 Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis

31 Liver Biopsy Findings for HIV-Infected Patients with Chronic Hepatitis C and Persistently Normal Levels of Alanine Aminotransferase

32 Simultaneous Acute Hepatitis B Virus and Hepatitis C Virus Infection Leading to Fulminant Hepatitis and Subsequent Chronic Hepatitis C

33 Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States

34 neuroimaging findings in chronic hepatitis c virus infection: correlation with neurocognitive and neuropsychiatric manifestations

35 viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis c cinética viral durante el primer mes de tratamiento en pacientes con hepatitis crónica c genotipo 1

36 characteristic morphological signs of the brain damage during chronic hepatitis c virus infection identified in autopsy samples

37 management of chronic hepatitis c: consensus guidelines

38 role of t-helper 9 cells in chronic hepatitis c-infected patients

39 treatment of chronic hepatitis c among injecting drug users: a 5-year follow-up

40 the treatment outcome and impact on blood transfusion demand of peg-interferon/ribavirin in thalassemic patients with chronic hepatitis c

41 case report: safety and efficacy of tocilizumab in a patient with rheumatoid arthritis and chronic hepatitis c

42 evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis c

43 direct acting antivirals in patients with chronic hepatitis c and down syndrome

44 population changes of colon lumen microbiota in patients with chronic hepatitis c

45 boceprevir-based triple antiviral therapy for chronic hepatitis c virus infection in kidney-transplant candidates

46 efficacy of interferon alpha- 2b with or without ribavirin in thalassemia major patients with chronic hepatitis c virus infection: a randomized, double blind, controlled, parallel group trial

47 retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis c who have relapsed or not responded to a first course of pegylated interferon-based therapy

48 comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis c:a retrospective study using the japanese interferon database

49 efficacy and safety of low-dose peginterferon alpha-2a plus ribavirin on chronic hepatitis c

50 il28b gene polymorphisms in mono- and hiv-coinfected chronic hepatitis c patients

51 patients with haemoglobinopathies and chronic hepatitis c: a really difficult to treat population in 2016?

52 metabolic factors and chronic hepatitis c: a complex interplay

53 chronic hepatitis c: an overview of evidence on epidemiology and management from a brazilian perspective

54 role of anti-mutated citrullinated vimentin antibodies in chronic hepatitis c patients and its relation to hcv associated arthritis

55 association of the nutritional profile with histological findings of patients with genotype 1 chronic hepatitis c infection

56 hepatocarcinoma en paciente con hepatitis crónica por vhc sin cirrosis hepatocellular carcinoma in a patient with chronic hepatitis c without cirrhosis

57 efficacy and safety of a novel pegylated interferon alpha-2a in egyptian patients with genotype 4 chronic hepatitis c

58 Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report.

59 Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.

60 Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals

61 An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens

62 Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

63 Analysis of Subgroup Differences in the ION-3 Trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C Infection

64 Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis

65 Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C

66 Sofosbuvir for previously untreated chronic hepatitis C infection

67 Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey.

Keyword Connections

Journals

Research Groups

Bibliographies